• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Benitec Biopharma Inc.

    4/29/24 11:44:13 AM ET
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BNTC alert in real time by email
    SC 13G 1 tm2412949d1_sc13g.htm SC 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

    SCHEDULE 13G

    (Rule 13d-102)

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO §240.13d-2

     

    Benitec Biopharma Inc.
    (Name of Issuer)

     

    Common Stock, $0.0001 par value
    (Title of Class of Securities)

     

    08205P100
    (CUSIP Number)

     

               April 22, 2024           
    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

      ¨ Rule 13d-1 (b)

     

      x Rule 13d-1 (c)

     

      ¨ Rule 13d-1 (d)

     

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    (Continued on following page(s))
    Page 1 of 7 Pages

     

     

     

     

     

    CUSIP No. 08205P100 13G Page 2 of 7 Pages

     

    1

    NAME OF REPORTING PERSON
    Nemean Asset Management, LLC

     

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨
    (b) x

    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION
    Florida

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    5

    SOLE VOTING POWER
    -0-

     

    6

    SHARED VOTING POWER
    746,324

     

    7

    SOLE DISPOSITIVE POWER
    -0-

     

    8

    SHARED DISPOSITIVE POWER
    746,324

     

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    746,324

     

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES   (SEE INSTRUCTIONS) ¨

     

     

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
    8.39%

     

    12

    TYPE OF REPORTING PERSON
    CO

     

                           

     

     

     

     

    CUSIP No. 08205P100 13G Page 3 of 7 Pages

      

    1

    NAME OF REPORTING PERSON
    IRA financial trust FBO Steven M. Oliveira Roth IRA

     

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨
    (b) x

    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION
    USA

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    5

    SOLE VOTING POWER
    0

     

    6

    SHARED VOTING POWER
    44,911

     

    7

    SOLE DISPOSITIVE POWER
    0

     

    8

    SHARED DISPOSITIVE POWER
    44,911

     

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    44,911

     

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES   (SEE INSTRUCTIONS) ¨

     

     

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
    0.01%

     

    12

    TYPE OF REPORTING PERSON
    OO

     

                           

     

     

     

     

    CUSIP No. 08205P100 13G Page 4 of 7 Pages

     

    1

    NAME OF REPORTING PERSON
    Steven M. Oliveira

     

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨
    (b) x

    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION
    U.S.A.

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    5

    SOLE VOTING POWER
    0

     

    6

    SHARED VOTING POWER
    791,235

     

    7

    SOLE DISPOSITIVE POWER
    0

     

    8

    SHARED DISPOSITIVE POWER
    791,235

     

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    791,235

     

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES   (SEE INSTRUCTIONS) ¨

     

     

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
    8.89%

     

    12

    TYPE OF REPORTING PERSON
    IN

     

                           

     

     

     

     

    CUSIP No. 08205P100 13G Page 5 of 7 Pages

     

    Item 1.

     

      (a) Name of Issuer: Benitec Biopharma Inc. (the "Company").

     

      (b) Address of Issuer's Principal Executive Offices:

     

    The Company's principal executive offices are located at 3940 Trust Way, Hayward, CA 94545.

     

    Item 2.

     

      (a) Name of Person Filing: Nemean Asset Management, LLC
          IRA financial trust FBO Steven M. Oliveira Roth IRA
          Steven Oliveira

     

      (b) Address of Principal Business Office or if none, Residence:

     

    Nemean Asset Management, LLC:

     207 Commodore Drive

    Jupiter, FL 33477

     

    IRA financial trust FBO Steven M. Oliveira Roth IRA:

    c/o Nemean Asset Management, LLC

    207 Commodore Drive

    Jupiter, FL 33477

     

    Steven Oliveira:

    c/o Nemean Asset Management, LLC

    207 Commodore Drive

    Jupiter, FL 33477

     

      (c) Citizenship: Nemean Asset Management, LLC – Florida

    IRA financial trust FBO Steven M. Oliveira Roth IRA: - U.S.A.

    Steven Oliveira – U.S.A.

     

      (d) Title of Class of Securities:  Common Stock, $0.0001 par value

     

      (e) CUSIP Number:  08205P100

     

    Item 3. Not Applicable

     

    Item 4. Ownership.

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

      (a) Amount Beneficially Owned:

     

    Nemean Asset Management, LLC – 746,324

     

    IRA financial trust FBO Steven M. Oliveira Roth IRA – 44,911

     

    Steven Oliveira – 791,235.

     

    Steven Oliveira has voting and dispositive power over the securities owned by Nemean Asset Management, LLC and the Roth IRA.

     

     

     

     

    CUSIP No. 08205P100 13G Page 6 of 7 Pages

     

      (b) Percent of Class:

     

    Nemean Asset Management, LLC – 8.39%

     

    IRA financial trust FBO Steven M. Oliveira Roth IRA – 0.01%

     

    Steven Oliveira – 8.89%

     

    The foregoing percentages are based upon a total of 8,898,946 shares of Common Stock.

     

     

      (c) Number of shares as to which such person has:

     

      (i) sole power to vote or to direct the vote:

     

    Nemean Asset Management, LLC – 0.

     

    IRA financial trust FBO Steven M. Oliveira Roth IRA - 0

     

    Steven Oliveira – 0

     

      (ii) shared power to vote or to direct the vote:

     

    Nemean Asset Management, LLC – 746,324

     

    IRA financial trust FBO Steven M. Oliveira Roth IRA – 44,911

     

    Steven Oliveira – 791,235

     

      (iii) sole power to dispose or to direct the disposition of:

     

    Nemean Asset Management, LLC – 0.

     

    IRA financial trust FBO Steven M. Oliveira Roth IRA - 0

     

    Steven Oliveira – 0

     

      (iv) shared power to dispose or to direct the disposition of:

     

    Nemean Asset Management, LLC – 746,324

     

    IRA financial trust FBO Steven M. Oliveira Roth IRA – 44,911

     

    Steven Oliveira – 791,235

     

    Item 5. Ownership of Five Percent or Less of a Class: No

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person: Not Applicable

     

    Item 7. Identification and Classification of Subsidiary Which Acquired the Securities: Not Applicable

     

    Item 8. Identification and Classification of Members of the Group: Not Applicable

     

    Item 9. Notice of Dissolution of Group: Not Applicable

     

    Item 10. Certifications: Not Applicable

     

     

     

     

    CUSIP No. 08205P100 13G Page 7 of 7 Pages

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    April 29, 2024

     

      NEMEAN ASSET MANAGEMENT, LLC
         
      By: /s/ Steven Oliveira
        Name: Steven Oliveira
        Title: Authorized Signatory
         
      IRA FINANCIAL TRUST FBO STEVEN M. OLIVEIRA ROTH IRA
         
        /s/ Steven Oliveira
         
      STEVEN M. OLIVEIRA
       
        /s/ Steven Oliveira
        Steven Oliveira

     

     

     

    Get the next $BNTC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BNTC

    DatePrice TargetRatingAnalyst
    5/12/2026$25.00Outperform
    Evercore ISI
    7/7/2025Buy
    TD Cowen
    12/16/2024$28.00Buy
    H.C. Wainwright
    12/13/2024$30.00Outperform
    Robert W. Baird
    10/16/2024$35.00Outperform
    Oppenheimer
    9/12/2024$17.00Buy
    Guggenheim
    7/22/2024$13.00Outperform
    Leerink Partners
    6/13/2024$30.00Overweight
    Piper Sandler
    More analyst ratings

    $BNTC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Evercore ISI initiated coverage on Benitec Biopharma with a new price target

    Evercore ISI initiated coverage of Benitec Biopharma with a rating of Outperform and set a new price target of $25.00

    5/12/26 8:44:41 AM ET
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TD Cowen initiated coverage on Benitec Biopharma

    TD Cowen initiated coverage of Benitec Biopharma with a rating of Buy

    7/7/25 8:17:08 AM ET
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright initiated coverage on Benitec Biopharma with a new price target

    H.C. Wainwright initiated coverage of Benitec Biopharma with a rating of Buy and set a new price target of $28.00

    12/16/24 6:46:22 AM ET
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BNTC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Friedman David Matthew

    4 - Benitec Biopharma Inc. (0001808898) (Issuer)

    5/28/26 9:10:14 PM ET
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Friedman David Matthew

    3 - Benitec Biopharma Inc. (0001808898) (Issuer)

    5/28/26 9:08:43 PM ET
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Mates Sharon

    4 - Benitec Biopharma Inc. (0001808898) (Issuer)

    1/26/26 4:10:15 PM ET
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BNTC
    SEC Filings

    View All

    Benitec Biopharma Inc. filed SEC Form 8-K: Leadership Update

    8-K - Benitec Biopharma Inc. (0001808898) (Filer)

    5/29/26 4:10:56 PM ET
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Benitec Biopharma Inc.

    10-Q - Benitec Biopharma Inc. (0001808898) (Filer)

    5/14/26 8:10:59 AM ET
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Benitec Biopharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Benitec Biopharma Inc. (0001808898) (Filer)

    5/14/26 8:09:20 AM ET
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BNTC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Suvretta Capital Management, Llc bought $1,903,133 worth of shares (144,223 units at $13.20) (SEC Form 4)

    4 - Benitec Biopharma Inc. (0001808898) (Issuer)

    12/29/25 7:31:28 PM ET
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Suvretta Capital Management, Llc bought $538,972 worth of shares (46,141 units at $11.68) (SEC Form 4)

    4 - Benitec Biopharma Inc. (0001808898) (Issuer)

    12/22/25 7:45:03 PM ET
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Suvretta Capital Management, Llc bought $19,999,994 worth of shares (1,481,481 units at $13.50) (SEC Form 4)

    4 - Benitec Biopharma Inc. (0001808898) (Issuer)

    11/10/25 9:51:33 PM ET
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BNTC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Benitec Biopharma Releases Third Quarter 2026 Financial Results and Provides Operational Update

    Late-breaking abstract for BB-301 presented at the Muscular Dystrophy Association (MDA) Clinical and Scientific Conference in March demonstrated durable responses to low dose BB-301 at 12-months and 24-months post-treatment and further improvements in depth of response following treatment with high dose BB-301 at the 3-month post-treatment follow-up time-point, with both doses demonstrating disease modifying outcomesBB-301 Phase 1b/2a interim clinical study results selected for oral presentation at the 2026 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting on May 15Advancement of Cohort 2 enrollment continues as Patient 1 and Patient 2 were both safely treated with high dose B

    5/14/26 8:00:00 AM ET
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Benitec Biopharma Announces Oral Presentation of Interim Phase 1b/2a Clinical Study Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 at the 2026 American Society of Gene and Cell Therapy Annual Meeting

    - Interim clinical results for the BB-301 Phase 1b/2a study include 12-month post-treatment follow-up results for the first four Cohort 1 completers, 24-month post-treatment follow-up results for the first Cohort 1 Patient, and interim clinical results for the first Cohort 2 Patient - BB-301 is the only clinical-stage therapeutic agent in development for the treatment of dysphagia in patients diagnosed with OPMD HAYWARD, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary "Silence and Replace" DNA-directed RNA in

    4/28/26 7:00:00 AM ET
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PureTech Founded Entity Seaport Therapeutics Adds Intra-Cellular Therapies Founder and CEO, Dr. Sharon Mates, to its Board of Directors

    PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value, notes that its Founded Entity, Seaport Therapeutics, today announced the appointment of Dr. Sharon Mates to its Board of Directors. Dr. Mates served as the Co-Founder, Chairman, and Chief Executive Officer of Intra-Cellular Therapies, Inc. from inception of the company in June 2002 until its acquisition by Johnson & Johnson (J&J) in 2025 for approximately $14.6 billion. She has decades of experience in neuropsychiatry, guiding a company she founded through successful commercialization and a major st

    4/27/26 7:05:00 AM ET
    $BNTC
    $PRTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BNTC
    Leadership Updates

    Live Leadership Updates

    View All

    PureTech Founded Entity Seaport Therapeutics Adds Intra-Cellular Therapies Founder and CEO, Dr. Sharon Mates, to its Board of Directors

    PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value, notes that its Founded Entity, Seaport Therapeutics, today announced the appointment of Dr. Sharon Mates to its Board of Directors. Dr. Mates served as the Co-Founder, Chairman, and Chief Executive Officer of Intra-Cellular Therapies, Inc. from inception of the company in June 2002 until its acquisition by Johnson & Johnson (J&J) in 2025 for approximately $14.6 billion. She has decades of experience in neuropsychiatry, guiding a company she founded through successful commercialization and a major st

    4/27/26 7:05:00 AM ET
    $BNTC
    $PRTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Seaport Therapeutics Adds Intra-Cellular Therapies Founder and CEO, Dr. Sharon Mates, to its Board of Directors

    Dr. Mates grew Intra-Cellular from discovery and early innovation through commercialization of CAPLYTA® and a $14.6 billion acquisition by Johnson & Johnson Seaport Therapeutics ("Seaport" or the "Company"), a clinical-stage therapeutics company that is inventing and developing neuropsychiatric medicines, today announced the appointment of Dr. Sharon Mates to its Board of Directors. Dr. Mates served as the Co-Founder, Chairman, and Chief Executive Officer of Intra-Cellular Therapies, Inc. from inception of the company in June 2002 until its acquisition by Johnson & Johnson (J&J) in 2025 for approximately $14.6 billion. She has decades of experience in neuropsychiatry, guiding a company

    4/27/26 7:00:00 AM ET
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Benitec Biopharma Announces Appointment of Sharon Mates Ph.D. to its Board of Directors

    HAYWARD, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary "Silence and Replace" DNA-directed RNA interference ("ddRNAi") platform, today announces the appointment of Dr. Sharon Mates to the board of directors (BOD) of the Company, effective November 2, 2025. "We are delighted to welcome Dr. Sharon Mates to Benitec's Board of Directors," said Jerel Banks, M.D., Ph.D., Chairman and Chief Executive Officer of Benitec Biopharma. "Dr. Mates brings exceptional leadership experience in building successful biotechnology c

    11/3/25 7:00:00 AM ET
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BNTC
    Financials

    Live finance-specific insights

    View All

    Benitec Biopharma Releases Full Year 2025 Financial Results and Provides Operational Update

    Interim Clinical Study Results for Cohort 1 of the BB-301 Phase 1b/2a Treatment Study Anticipated in Q4 2025 Enrollment of the First Subject into Cohort 2 of the BB-301 Phase 1b/2a Treatment Study Expected in Q4 2025 HAYWARD, Calif., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary "Silence and Replace" DNA-directed RNA interference ("ddRNAi") platform, today announced financial results for its full year ended June 30, 2025. The Company has filed its annual report on Form 10-K with the U.S. Securities and Exchange Commi

    9/22/25 4:05:00 PM ET
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Benitec Biopharma Releases Third Quarter 2025 Financial Results

    HAYWARD, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary "Silence and Replace" DNA-directed RNA interference ("ddRNAi") platform, today announced financial results for its third fiscal quarter ended March 31, 2025. The Company has filed its quarterly report on Form 10-Q with the U.S. Securities and Exchange Commission. "We are profoundly honored to be closely engaged with the OPMD patient community and are thankful for the support of the Subjects and their families as we remain focused on the continued development

    5/14/25 7:00:00 AM ET
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Benitec Biopharma Releases Second Quarter 2025 Financial Results and Provides Operational Update

    -Fifth Subject in BB-301 Phase 1b/2a Clinical Treatment Study safely treated in February 2025- -Interim clinical study update to be presented in late-breaking oral presentation at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference on March 19, 2025- HAYWARD, Calif., Feb. 14, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary "Silence and Replace" DNA-directed RNA interference ("ddRNAi") platform, today announced financial results for its second fiscal quarter ended December 31, 2024. The Company has filed its

    2/14/25 8:10:00 AM ET
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BNTC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Benitec Biopharma Inc.

    SC 13G/A - Benitec Biopharma Inc. (0001808898) (Subject)

    12/6/24 1:47:28 PM ET
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Benitec Biopharma Inc.

    SC 13D/A - Benitec Biopharma Inc. (0001808898) (Subject)

    11/18/24 4:36:00 PM ET
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Benitec Biopharma Inc.

    SC 13G/A - Benitec Biopharma Inc. (0001808898) (Subject)

    11/14/24 1:37:20 PM ET
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care